FDA grants orphan status for Amarantus' eltoprazine to treat PD-LID
The US Food and Drug Administration (FDA) has granted orphan drug designation for Amarantus BioScience Holdings' (AMBS') eltoprazine to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Carbidopa/Levodopa | Dyskinesia | Food and Drug Administration (FDA) | Grants | Parkinson's Disease | Pharmaceuticals